Primary Care Pathways Survey

1. Please enter the name of your CCG
2. Do you have a named person within the CCG who is responsible for liver disease?
Options: Yes No
If yes, please answer Q3 and then move to Q5 If no, please answer Q4 and then move to Q5
3. Please provide the details of the person responsible for liver disease within the CCG
4. In the absence of a named contact for liver disease at the CCG, please provide the details of the person who should be contacted regarding liver health
5. Do you have a commissioned pathway for:a) the interpretation of abnormal liver blood tests?b) responding to liver disease more generally?
Options: Yes, pathways for both Yes, pathway for abnormal liver blood tests Yes, pathway for responding to liver disease more generally No pathways for either
If answer to any of these is yes, please move to Q6 If answer is no pathways for either, please move to Q9
6. Does it include an endorsed pathway for the management of abnormal liver blood tests that follow the BSG guidance?
Options: Yes No
7. Is liver fibrosis assessment part of your pathway?
Options: Yes No
If yes, please move to Q8 If no, please move to Q9

8. Please indicate how fibrosis is assessed. Please tick all that apply
Options: Fibroscan (transient elastography) ELF Test FIB-4 score NAFLD fibrosis score Other (please specify)
9. Do you have an additional pathway that proactively case-finds individuals who may be at high-risk of liver disease? e.g. people with diabetes or for those who drink alcohol at harmful levels
Options: Yes No
If yes, please move to Q10 If no, please move to Q12
10. How does your pathway define individuals as high risk of liver disease? Please tick all that apply
Options: Diabetes Alcohol risk Obesity Obesity with other metabolic risk factors Risk factors for viral hepatitis Other (please specify)
11. How are these individuals identified? Please tick all that apply
Options: At annual chronic disease / year of care review During the NHS health check Opportunistically during consultations Using IT system prompts / pop-ups Other (please specify)
12. Does the CCG monitor the breadth of adoption and efficacy of pathways in primary care your area?
Options: Yes No

If yes, please move to Q13
If no, please move to Q14

- 13. Where are these statistics published?
- 14. Are you aware of the current available statistics relating to liver disease in your area and do you monitor these?

Options
Yes

No

15. Would you be willing to share your pathway information with other CCGs for best practice purposes?

If yes, we will email you for further details.

Options:

Yes

No

END OF SURVEY